We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; ba... Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. Show more
Allegations of ballot manipulation, legal precedent and forum shopping pose major obstacles to company’s plan Attorneys representing tens of thousands of women with ovarian cancer linked to use...
Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately...
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated...
Microsoft (NASDAQ:MSFT), Vodafone (NASDAQ:VOD) – Microsoft announced a new stock buyback program of up to $60 billion and a 10% increase in its quarterly dividend to $0.83. The company plans to...
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer PR Newswire BARCELONA...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer PR Newswire BARCELONA, Spain, Sept. 15, 2024...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer PR Newswire BARCELONA, Sept. 14, 2024 Median duration of response reaches 7.4...
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer PR Newswire BARCELONA, Sept...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.2 | -1.32243327723 | 166.36 | 168.35 | 163.55 | 6224546 | 165.46915221 | CS |
4 | -0.13 | -0.0791283705642 | 164.29 | 168.85 | 162.16 | 6017530 | 165.44916943 | CS |
12 | 17.99 | 12.3075870562 | 146.17 | 168.85 | 144.5 | 6521689 | 159.30819533 | CS |
26 | 8.81 | 5.67106533634 | 155.35 | 168.85 | 143.13 | 7102080 | 153.39960923 | CS |
52 | 4.09 | 2.55513212969 | 160.07 | 168.85 | 143.13 | 7055455 | 154.80029736 | CS |
156 | -0.33 | -0.200620098486 | 164.49 | 186.69 | 143.13 | 8534145 | 164.40275851 | CS |
260 | 33.14 | 25.2938482674 | 131.02 | 186.69 | 109.16 | 8137885 | 158.920347 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions